Clinicopathological and prognostic significance of PKM2 protein expression in cirrhotic hepatocellular carcinoma and non-cirrhotic hepatocellular carcinoma

[1]  Weiwei Yang,et al.  PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis , 2016, Nature Communications.

[2]  A. Molinaro,et al.  PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells , 2016, International journal of cancer.

[3]  Tingting Yang,et al.  PKM2 Thr454 phosphorylation increases its nuclear translocation and promotes xenograft tumor growth in A549 human lung cancer cells. , 2016, Biochemical and biophysical research communications.

[4]  D. Dhar,et al.  Pyruvate Kinase M2 and Lactate Dehydrogenase A Are Overexpressed in Pancreatic Cancer and Correlate with Poor Outcome , 2016, PloS one.

[5]  Li Yang,et al.  MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer , 2016, Oncotarget.

[6]  K. Xie,et al.  PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma , 2015, Molecular Cancer.

[7]  W. Xu,et al.  Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells. , 2015, World journal of gastroenterology.

[8]  H. Wang,et al.  AROS Is a Significant Biomarker for Tumor Aggressiveness in Non-cirrhotic Hepatocellular Carcinoma , 2015, Journal of Korean medical science.

[9]  Y. Akao,et al.  MicroRNA-124 inhibits cancer cell growth through PTB1/PKM1/PKM2 feedback cascade in colorectal cancer. , 2015, Cancer letters.

[10]  H. Furukawa,et al.  Differential reactivation of fetal/neonatal genes in mouse liver tumors induced in cirrhotic and non-cirrhotic conditions , 2015, Cancer science.

[11]  Di Chen,et al.  Co-expression of PKM2 and TRIM35 predicts survival and recurrence in hepatocellular carcinoma , 2014, Oncotarget.

[12]  Yongsheng Fan,et al.  PKM2 depletion induces the compensation of glutaminolysis through β-catenin/c-Myc pathway in tumor cells. , 2014, Cellular signalling.

[13]  Carlo La Vecchia,et al.  Hepatocellular carcinoma epidemiology. , 2014, Best practice & research. Clinical gastroenterology.

[14]  Xianghuo He,et al.  TRIM35 Interacts with pyruvate kinase isoform M2 to suppress the Warburg effect and tumorigenicity in hepatocellular carcinoma , 2014, Oncogene.

[15]  Georgios S. Ioannidis,et al.  PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer , 2014, British Journal of Cancer.

[16]  Zongwei Li,et al.  Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling. , 2014, Cellular signalling.

[17]  Q. Zou,et al.  PKM2 and ACVR 1C are prognostic markers for poor prognosis of gallbladder cancer , 2014, Clinical and Translational Oncology.

[18]  H. Kung,et al.  JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1α–mediated glucose metabolism , 2013, Proceedings of the National Academy of Sciences.

[19]  Y. Xiong,et al.  Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. , 2013, Molecular cell.

[20]  Weiwei Yang,et al.  Nuclear PKM2 regulates the Warburg effect , 2013, Cell cycle.

[21]  H. Christofk,et al.  New aspects of the Warburg effect in cancer cell biology. , 2012, Seminars in cell & developmental biology.

[22]  J. Bruix,et al.  Hepatocellular carcinoma , 2012, The Lancet.

[23]  Xueliang Gao,et al.  Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. , 2012, Molecular cell.

[24]  K. Aldape,et al.  Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation , 2011, Nature.

[25]  G. Semenza,et al.  Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1 in cancer cells , 2011, Oncotarget.

[26]  Zhengyu Zha,et al.  Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. , 2011, Molecular cell.

[27]  Matthew K. Knabel,et al.  Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1 , 2011, Cell.

[28]  Xiaolong Yang,et al.  Molecular mechanism of size control in development and human diseases , 2011, Cell Research.

[29]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[30]  Ming-Rong Wang,et al.  Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth , 2011, Proceedings of the National Academy of Sciences.

[31]  V. Santi,et al.  Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[32]  T. Seyfried,et al.  Cancer as a metabolic disease , 2010, Nutrition & metabolism.

[33]  A. Fisk,et al.  Univariate and Multivariate Analysis of Variance: A Primer , 2009 .

[34]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[35]  Li Xu,et al.  Clinicopathologic Features and Long-Term Outcomes of Chinese Patients with Hepatocellular Carcinoma in Non-Cirrhotic Liver , 2008, Digestive Surgery.

[36]  D. Sabatini,et al.  Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.

[37]  H. Brenner,et al.  Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study , 2008, British Journal of Cancer.

[38]  J. Bruix,et al.  Management of hepatocellular carcinoma , 2005, Hepatology.

[39]  B. le Bail,et al.  Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. , 2005, Journal of the American College of Surgeons.

[40]  D. Brenner,et al.  Erratum: Liver fibrosis (Journal of Clinical Investigation (2005) 115 (209-218) DOI:10.1172/JCI200524282) , 2005 .

[41]  R. Bagga,et al.  Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2‐PK) as a tumor marker for cervical carcinoma , 2004, The journal of obstetrics and gynaecology research.

[42]  L. Jeng,et al.  Prognostic Factors after Resection for Hepatocellular Carcinoma in Noncirrhotic Livers: Univariate and Multivariate Analysis , 2003, World Journal of Surgery.

[43]  T. Tanaka,et al.  The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing. , 1986, The Journal of biological chemistry.

[44]  O. Warburg.  On the origin of cancer cells. , 1956, Science.

[45]  M. Hung,et al.  Extracellular PKM2 induces cancer proliferation by activating the EGFR signaling pathway. , 2016, American journal of cancer research.

[46]  G. Collins.  The next generation. , 2006, Scientific American.

[47]  R. Bataller,et al.  Amendment history : Corrigendum ( April 2005 ) Liver fibrosis Ramón Bataller , 2018 .